CRISPR-Cas9 Gene Therapy: Non-Viral Delivery and Stimuli-Responsive Nanoformulations
Molecules · 24.01.2025 · 30 (3) · 542
DOI: 10.3390/molecules30030542 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 24.01.2025. Verfasst von Hyunwoo Lee und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioscience and Biotechnology, Konkuk University, Seoul 05029, Republic of Korea. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Genetic Therapy, Gene Editing, Nanoparticles. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 214 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and ICT, Bio and Medical Technology Development Program, National Research Foundation of Korea (NRF).
Abstract (Originalsprache)
The CRISPR-Cas9 technology, one of the groundbreaking genome editing methods for addressing genetic disorders, has emerged as a powerful, precise, and efficient tool. However, its clinical translation remains hindered by challenges in delivery efficiency and targeting specificity. This review provides a comprehensive analysis of the structural features, advantages, and potential applications of various non-viral and stimuli-responsive systems, examining recent progress to emphasize the potential to address these limitations and advance CRISPR-Cas9 therapeutics. We describe how recent reports emphasize that nonviral vectors, including lipid-based nanoparticles, extracellular vesicles, polymeric nanoparticles, gold nanoparticles, and mesoporous silica nanoparticles, can offer diverse advantages to enhance stability, cellular uptake, and biocompatibility, based on their structures and physio-chemical stability. We also summarize recent progress on stimuli-responsive nanoformulations, a type of non-viral vector, to introduce precision and control in CRISPR-Cas9 delivery. Stimuli-responsive nanoformulations are designed to respond to pH, redox states, and external triggers, facilitate controlled and targeted delivery, and minimize off-target effects. The insights in our review suggest future challenges for clinical applications of gene therapy technologies and highlight the potential of delivery systems to enhance CRISPR-Cas9’s clinical efficacy, positioning them as pivotal tools for future gene-editing therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Bioscience and Biotechnology, Konkuk University, Seoul 05029, Republic of Korea.
- School of International Engineering and Science, Jeonbuk National University, Jeonju 54896, Republic of Korea.
- Division of Science Education, Kangwon National University, 1 Gangwondaehakgil, Chuncheon-si 24341, Republic of Korea.
ORCID-Profile: Hyunwoo Lee, Won-Yeop Rho, Hyejin Chang, Bong-Hyun Jun
Förderung
- Ministry of Science and ICT
- Bio and Medical Technology Development Program
- National Research Foundation of Korea (NRF)
Zitieren
APA
Lee, H., Rho, W. Y., Kim, Y. H., Chang, H., & Jun, B. H. (2025). CRISPR-Cas9 Gene Therapy: Non-Viral Delivery and Stimuli-Responsive Nanoformulations. Molecules, 30(3), 542. https://doi.org/10.3390/molecules30030542
Vancouver
Lee H, Rho WY, Kim YH, Chang H, Jun BH. CRISPR-Cas9 Gene Therapy: Non-Viral Delivery and Stimuli-Responsive Nanoformulations. Molecules. 2025;30(3):542. doi:10.3390/molecules30030542
BibTeX
@article{Lee2025,
author = {Lee, Hyunwoo and Rho, Won-Yeop and Kim, Yoon-Hee and Chang, Hyejin and Jun, Bong-Hyun},
title = {CRISPR-Cas9 Gene Therapy: Non-Viral Delivery and Stimuli-Responsive Nanoformulations},
journal = {Molecules},
year = {2025},
volume = {30},
number = {3},
pages = {542},
doi = {10.3390/molecules30030542}
}
EUVIMED